ClinicalTrials.gg
Enrolling by invitationNCT07239557Updated May 15, 2026

Optimal Interval for Periodic Alveolar Recruitment Maneuvers Achieving 90% Lung Re-expansion During Intraoperative Ventilation

An interventional study of Different interval of PARM in Major Abdominal Surgery, Atelectasis and Lung-protective Ventilation, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Enrolling by invitation at 1 site in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Pulmonary Atelectasis with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Pulmonary Atelectasis · China.

Planned enrollment
17th of 21
52 · median 90
Started
2025
with 4 others
No phase
19 of 24
12 open now
Primary completion
2026-12
later than 9 of 13 live
Registered
16th of 24
by date
Lead sponsor
2 of 24
Sixth Affiliated Hospital, Sun Yat-sen University

Among the 24 studies in Pulmonary Atelectasis with a site in China, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 19 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 16th registered.

Pulmonary Atelectasis

378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.

Browse Pulmonary Atelectasis studies →

Open to participants now

13 of the 24 studies in Pulmonary Atelectasis with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Pulmonary Atelectasis with a site in China, or all of them as a file.
02

Study summary

This study aims to determine the optimal interval for periodic alveolar recruitment maneuvers (PARM) that can achieve effective lung re-expansion in 90% of patients undergoing intraoperative mechanical ventilation during abdominal laparoscopic surgery in the low Trendelenburg position. Identifying the most effective frequency of PARM is crucial for establishing lung-protective ventilation strategies, with the ultimate goal of reducing intraoperative atelectasis, decreasing postoperative pulmonary complications, and accelerating recovery.

Patients are randomized using a biased-coin sequential design. PARM is initially applied every 0.5 hours, and the effectiveness of lung re-expansion is evaluated before the end of surgery. The primary outcome is the effectiveness of recruitment, assessed by a combination of lung ultrasound scores and shunt fraction. Secondary outcomes include mechanical power at the end of surgery, time-weighted average mechanical power during ventilation, postoperative P/F ratio, dead space fraction, air test results, intraoperative adverse events, incidence of respiratory failure in the PACU and postoperative period, and postoperative length of stay.

This trial is expected to provide robust evidence for defining the optimal RM interval in protective ventilation protocols for patients undergoing laparoscopic abdominal surgery, thereby contributing to improved perioperative respiratory outcomes.

Read the detailed description

This study is designed to evaluate the optimal interval of periodic alveolar recruitment maneuvers (PARM) to achieve effective lung re-expansion (defined as LUS ≤1 and shunt fraction \<10%) in 90% of elderly patients undergoing laparoscopic anterior resection in low Trendelenburg position. This is a single-arm, biased-coin sequential design study. The initial PARM interval is 30 min, adjusted in 10 min increments based on response. The primary outcome is recruitment efficacy. Secondary outcomes include intraoperative mechanical power, P/F ratio, postoperative pulmonary complications, and length of hospital stay. This study aims to inform optimal RM intervals in protective ventilation protocols.

03

Conditions studied

  • Major Abdominal Surgery
  • Atelectasis
  • Lung-protective Ventilation
  • Lung Ultrasound Score
  • Postoperative Pulmonary Complications

Browse trials for

Keywords

  • Laparoscopy
  • Trendelenburg position
  • Major abdominal surgery
  • Mechanical ventilation
  • Periodic recruitment maneuvers
  • Lung recruitment strategy
  • Respiratory function
  • Lung-protective ventilation
  • Lung ultrasound score
  • Effective concentration for 90% (EC90)
04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65-80 years
  • Undergoing elective laparoscopic anterior resection (expected mechanical ventilation duration 2-5 hours)
  • Intermediate risk for postoperative pulmonary complications
  • Room air SpO₂ ≥94%

Exclusion criteria

Exclusion Criteria:

  • History of pneumonia within 1 month or mechanical ventilation ≥1 hour
  • Preoperative 12-zone LUS with any single zone score ≥2
  • Preoperative shunt fraction ≥10%
  • Progressive neuromuscular disease
  • Severe emphysema/ or subpleural bullae ≥2 cm
  • Intracranial hypertension
  • Participation in other studies or refusal to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    PARM

    Procedure: Different interval of PARM

Interventions

  • ProcedureDifferent interval of PARM

    The initial time interval of PARM was 0.5 hours/time, and the different interval of PARM was assigned by random partial coin sequential method.If the previous patient did not respond to postoperative assessment of lung opening, the interval between expansion of the lungs was shortened by 10 minutes for the next patient; If lung opening is effective, there is an 11% chance that the next patient will have an 10-minute expansion interval and an 89% chance that the time interval will remain unchanged.

06

What researchers measure

Primary outcomes

  1. The effectiveness of recruitment

    The effectiveness of recruitment assessed by a combination of lung ultrasound scores and shunt fraction。At the end of surgery (with the patient in the supine position, after at least 5 minutes of apnea under mechanical ventilation without spontaneous breathing, and at the specified interval since the last recruitment maneuver), a lung ultrasound examination was performed. Lung re-expansion was considered effective if the 12-zone lung ultrasound score (LUS) was ≤1 per zone and the shunt fraction was \<10%.

    Time frame: Intraoperative

Secondary outcomes

  1. Mechanical power at the end of surgery

    Mean or median mechanical power

    Time frame: With the patient in the supine position, after at least 5 minutes of apnea under mechanical ventilation without spontaneous breathing, and at the specified interval since the last recruitment maneuver

  2. Time-weighted average mechanical power during surgery

    Mechanical power per ventilation time

    Time frame: During intraoperative mechanical ventilation

  3. The P/F ratio at the end of surgery,

    P/F ratio = PaO₂ / FiO₂.Statistical measure: Incidence of P/F ratio ≤400. The P/F ratio is an objective research parameter, and a P/F ratio ≤400 indicates the presence of atelectasis.

    Time frame: At the end of surgery (with the patient in the supine position, after at least 5 minutes of apnea under mechanical ventilation without spontaneous breathing, and at the specified interval since the last recruitment maneuver)

  4. Dead space rate

    Arterial carbon dioxide partial pressure (PaCO2); partial pressure of carbon dioxide in end expiratory gas (PetCO2); Dead space fraction = (PaCO2-PetCO2)/ PaCO2.

    Time frame: At the end of surgery (with the patient in the supine position, after at least 5 minutes of apnea under mechanical ventilation without spontaneous breathing, and at the specified interval since the last recruitment maneuver)

  5. Air-breathing test

    After completion of ultrasound and arterial blood gas measurements, the inspired oxygen concentration was adjusted to 21%. SpO₂ was observed and recorded after 5 minutes.The incidence of a positive air-breathing test, defined as SpO₂ ≤96%, was recorded

    Time frame: At the end of surgery (with the patient in the supine position, after at least 5 minutes of apnea under mechanical ventilation without spontaneous breathing, and at the specified interval since the last recruitment maneuver)

  6. Intraoperative hypotension

    Defined as mean arterial pressure (MAP) \<60 mmHg from any cause, lasting for more than 3 minutes。

    Time frame: During mechanical ventilation in the intraoperative period.

  7. Intraoperative vasopressor use.

    Defined as any episode of MAP \<60 mmHg during mechanical ventilation requiring the administration of catecholamine vasopressors, including dopamine, epinephrine, or norepinephrine. Occurrence of such an event was recorded as positive.

    Time frame: During intraoperative mechanical ventilation

  8. Intraoperative mild hypoxemia

    SpO₂ ≤96% lasting for more than 3 minutes

    Time frame: During intraoperative mechanical ventilation

  9. Intraoperative severe hypoxemia

    SpO₂ ≤92% lasting for more than 3 minutes

    Time frame: During intraoperative mechanical ventilation

  10. Lung ultrasound score (LUS) in the post-anesthesia care unit (PACU)

    The 12-zone lung ultrasound score (LUS) ranges from 0 to 3 per zone (total 0-36). Higher scores indicate more severe atelectasis.

    Time frame: Awake with spontaneous breathing before discharge from the PACU

  11. Rate of respiratory failure at post-anesthesia care unit (PACU)

    PaO₂/FiO₂ \<300 mmHg, or PaO₂ \<60 mmHg or SpO₂ \<90% while awake and breathing room air.

    Time frame: Stay in the PACU for at least 20 minutes and at most 3 hours; assessed at 5 to 10 minutes before leaving PACU

  12. Rate of postoperative respiratory failure

    PaO₂/FiO₂ \<300 mmHg, or PaO₂ \<60 mmHg or SpO₂ \<90% while awake and breathing room air.

    Time frame: Day1 to 5 after surgery

  13. Rate of sustained hypoxaemia

    Sustained hypoxaemia, hypoxaemia at any two consecutive days; hypoxaemia: during a follow-up visit when the patient was awake and breathing room air, SpO2 ≤ 92% or the change of SpO2 (ΔSpO2, preoperative SpO2 minus postoperative SpO2) ≥ 5%.

    Time frame: Day 1 to 5 after surgery

  14. Postoperative pulmonary complications, Grades 1-4

    Operational Definitions of Postoperative Pulmonary Complications (Doi: 10.1001/jama.296.15.1851), graded on a scale from 1 to 4.

    Time frame: Day 0 to 5 after surgery

  15. Postoperative pulmonary complications, Grades 2-4

    Operational Definitions of Postoperative Pulmonary Complications (Doi: 10.1001/jama.296.15.1851), graded on a scale from 2 to 4

    Time frame: Day 0 to 5 after surgery

  16. Pneumothorax

    Defined as the presence of air within the pleural cavity, with the visceral pleura not being surrounded by a vascular pattern.

    Time frame: Day 0 to 7 after surgery

  17. Postoperative hospitalization days

    The duration between the operation date and the actual discharge date.

    Time frame: Day 0 to 30 after surgery

  18. Unexpected admission to ICU

    It does not include the patients who enter ICU at the request of surgeons but have normal spontaneous breathing, stable circulation and no disturbance of consciousness.

    Time frame: within 30 days after surgery

  19. Death from any cause

    Intraoperative or postoperative death from any cause

    Time frame: Day 0 to 30 after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 155 non-industry interventional studies with no phase under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 12 months is close to that.

Counting every sponsor, half of 157 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Nov 20, 2025
StartActual
Dec 10, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07239557
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Dec 10, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion